Prescient Therapeutics Limited (AU:PTX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Prescient Therapeutics has reported a successful quarter with positive feedback from an international T-cell lymphoma conference on its Phase 1b study of PTX-100, and a complete response from the last patient in the trial. The company maintains a healthy cash reserve of $14.5 million and is refining the Phase 2 trial design with expert input to address unmet medical needs in T-cell lymphomas. Prescient plans to engage with the FDA for the upcoming Phase 2 trial, aiming for a commencement before year’s end, while also advancing their cell therapy platforms and cell therapy development activities.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.